- 作者：Giovanni B. Frisoni ; Annapaola Prestia ; Orazio Zanetti ; Samantha Galluzzi ; Melissa Romano ; Maria Cotelli ; Massimo Gennarelli ; Giuliano Binetti ; Luisella Bocchio ; Barbara Paghera ; Giovanni Amicucci ; Matteo Bonetti ; Luisa Benussi ; Roberta Ghidoni ; Cristina Geroldi
- 关键词：Alzheimer's disease ; Biological markers ; Mild cognitive impairment ; Preclinical diagnosis
- 刊名：Alzheimer's Dementia
- 出版年：2009
- 出版时间：July 2009
- 年：2009
- 卷：5
- 期：4
- 页码：307-317
- 全文大小：688 K
BackgroundNew marker-based criteria for the diagnosis of Alzheimer's disease (AD) were recently proposed. We describe their operational translation in 144 consecutive patients referred to our Memory Clinic.Methods
Visual ratings of hippocampal atrophy and of cortical glucose hypometabolism in magnetic resonance imaging and positron emission tomography, and concentrations of total tau and Aβ1-42 in cerebrospinal fluid were assessed in 12 patients with subjective memory complaints (SMCs) (Mini-Mental State Examination [MMSE] score, 28.0 ± 1.1 [mean ± SD]), 37 with mild cognitive impairment (MCI) (MMSE, 25.1 ± 3.6), 55 with AD (MMSE, 21.1 ± 3.5), and 40 with non-AD dementia (MMSE, 21.6 ± 5.5).
Results
The sensitivity for AD of each individual biomarker was higher (65 % to 87 % ) than for MCI (18 % to 50 % ). Each biomarker's specificity for SMC and non-AD dementias was good to moderate (83 % and 53 % ). Positivity for at least one marker increased the probability 38 times of belonging to the AD group (P < 0.0001).
Conclusion
The new diagnostic criteria can be operationalized in clinical routines, but longitudinal studies of MCI patients will need to assess the criteria's prognostic value.